- Prestige Biopharma Joins CancerX as a Member
- Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer
- Prestige Biopharma Requests FDA Fast Track Designation for Its First-in-Class Pancreatic Cancer Treatment PBP1510
- Final Analysis of Phase 3 Clinical Trial of Prestige Biopharma’s HD201 published in ‘BMC Cancer’
No comments to show.